Abstract
A significant expansion of knowledge in the last few years, especially in the molecular biology of frontotemporal dementia (FTD) is summarized. This condition, formerly known as Picks disease and considered rare, is estimated to be 12-15% of all dementias and 30-50% early onset ones. The clinical picture is protean, mainly a behavioural and language impairment, but the extrapyramidal syndromes of CBD and PSP are often seen and conversely FTD and progressive aphasia often has motor symptoms, including ALS . These seemingly different presentations converge, as one or other areas in the brain are affected. Our experience with FTD in a clinical cohort, with high rate of autopsy confirmation is presented. Less than half of the cases are tauopathies, the majority has been discovered to have a TDP-43 and most recently a FUS proteinopathy, shared with ALS, opening potential opportunities for pharmacological approaches to treatment. Tau and progranulin mutations on Ch-17 and some others, point to molecular mechanisms. A glossary is provided to navigate the complex terminology.
Keywords: Frontotemporal dementia, progressive aphasia, semantic dementia, corticobasal degeneretion, progressive supranuclear palsy, tauopathies, TDP-43, ubiquitin, FUS, Pick bodies, PPA, bvFTD, CBD, NIIs
Current Alzheimer Research
Title: The Overlapping Syndromes of the Pick Complex
Volume: 8 Issue: 3
Author(s): A. Kertesz and P. McMonagle
Affiliation:
Keywords: Frontotemporal dementia, progressive aphasia, semantic dementia, corticobasal degeneretion, progressive supranuclear palsy, tauopathies, TDP-43, ubiquitin, FUS, Pick bodies, PPA, bvFTD, CBD, NIIs
Abstract: A significant expansion of knowledge in the last few years, especially in the molecular biology of frontotemporal dementia (FTD) is summarized. This condition, formerly known as Picks disease and considered rare, is estimated to be 12-15% of all dementias and 30-50% early onset ones. The clinical picture is protean, mainly a behavioural and language impairment, but the extrapyramidal syndromes of CBD and PSP are often seen and conversely FTD and progressive aphasia often has motor symptoms, including ALS . These seemingly different presentations converge, as one or other areas in the brain are affected. Our experience with FTD in a clinical cohort, with high rate of autopsy confirmation is presented. Less than half of the cases are tauopathies, the majority has been discovered to have a TDP-43 and most recently a FUS proteinopathy, shared with ALS, opening potential opportunities for pharmacological approaches to treatment. Tau and progranulin mutations on Ch-17 and some others, point to molecular mechanisms. A glossary is provided to navigate the complex terminology.
Export Options
About this article
Cite this article as:
Kertesz A. and McMonagle P., The Overlapping Syndromes of the Pick Complex, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563791
DOI https://dx.doi.org/10.2174/156720511795563791 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Current Pharmaceutical Design An Overview and Therapeutic Promise of Nutraceuticals Against Sports-Related Brain Injury
Current Molecular Pharmacology Age-Related Sleep Changes and its Implication in Neurodegenerative Diseases
Current Aging Science The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Secondary Prevention of Atherothrombotic Cerebrovascular Events
Current Vascular Pharmacology Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Current Pharmaceutical Design Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology The Use of Proteomics to Study Infectious Diseases
Infectious Disorders - Drug Targets Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Editorial [Hot topic: A Multi-Targeted Approach for a Complex Multifaceted Disease (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design Formulation and Assessment of In Vivo Anti-Inflammatory Potential of Omega-3-Fatty Acid Loaded Self Emulsifying Nanoemulsion
Current Nanomedicine Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy